This is the first-in-human study of BG-A3004. The study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of BG-A3004 after single and multiple doses administered in different dose levels in healthy participants (Part A) and patients with immune-mediated skin diseases (Part B), respectively.
Study details include:
* The study duration will be approximately 3 years.
* The treatment duration will be 1 dose for Part A and 4 doses for Part B.
* Safety follow-up period is 168 days after the last dose